Bullseye Asset Management LLC Has $1.65 Million Holdings in OptimizeRx Co. (NASDAQ:OPRX)

Bullseye Asset Management LLC grew its position in shares of OptimizeRx Co. (NASDAQ:OPRX) by 55.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 214,046 shares of the company’s stock after buying an additional 76,458 shares during the quarter. Bullseye Asset Management LLC owned approximately 1.17% of OptimizeRx worth $1,652,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Janney Montgomery Scott LLC acquired a new stake in OptimizeRx in the third quarter valued at approximately $810,000. Rice Hall James & Associates LLC raised its holdings in shares of OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after purchasing an additional 119,306 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of OptimizeRx by 101.8% in the 2nd quarter. Renaissance Technologies LLC now owns 142,146 shares of the company’s stock valued at $1,421,000 after purchasing an additional 71,700 shares during the last quarter. Vanguard Group Inc. boosted its holdings in OptimizeRx by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after purchasing an additional 6,291 shares in the last quarter. Finally, First Light Asset Management LLC increased its position in OptimizeRx by 5.1% during the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after buying an additional 89,377 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Down 2.4 %

OPRX opened at $5.23 on Tuesday. The business has a 50 day moving average of $5.75 and a 200-day moving average of $8.23. The stock has a market capitalization of $96.34 million, a price-to-earnings ratio of -3.93 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $16.65.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. JMP Securities decreased their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Stifel Nicolaus lowered their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Barclays reduced their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th. Finally, Roth Mkm reiterated a “buy” rating and issued a $16.00 target price (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, OptimizeRx has a consensus rating of “Moderate Buy” and an average price target of $10.42.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.